Enimmune Corporation (TPEX:6564)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
18.15
-0.45 (-2.42%)
Apr 20, 2026, 12:55 PM CST
Market Cap1.34B -28.6%
Revenue (ttm)48.19M +20.7%
Net Income-164.35M
EPS-2.28
Shares Out72.13M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1
Average Volume145,850
Open18.80
Previous Close18.60
Day's Range18.10 - 18.80
52-Week Range14.65 - 23.90
Beta0.35
RSI52.52
Earnings DateAug 11, 2026

About Enimmune

Enimmune Corporation engages in the research, development, and sale of drugs in Taiwan. The company offers EnVAX-A71, AimFlu-S(QIS), tetanus vaccine adsorbed suspension for injection, COVID-19 Ag rapid test, vaccines, test reagents, and related western medicines, as well as biotechnology services. It is also involved in the development of vaccines for the prevention of infectious diseases, including pneumococcus, norovirus, dengue fever virus, and Middle East respiratory syndrome, such as cell culture-derived Japanese encephalitis vaccine, whic... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 38
Stock Exchange Taipei Exchange
Ticker Symbol 6564
Full Company Profile

Financial Performance

In 2025, Enimmune's revenue was 48.19 million, an increase of 20.74% compared to the previous year's 39.92 million. Losses were -164.35 million, 4.32% more than in 2024.

Financial Statements